Subscribe Now

By entering these details you are signing up to receive our newsletter.


PID and plasma-derived therapies

We are so pleased to continue our partnership with CSL Behring with the launch of our second spotlight edition in the series, looking at confronting the challenges of primary immunodeficiencies, not just in the Middle East and Africa but at a global level.

We would like to thank CSL Behring for their continued partnership on this project. We would also like to thank all the contributors who so generously gave their time and insight to raise the profile of rare disease.

Plasma Ecomonics

CSL Behring operates one of the world’s largest plasma collection networks and is invested in delivering immunoglobulin (IG) therapies to treat rare conditions. Camilla Shen, executive director of CSL Behring, ECI, talks about the challenges in producing sufficient IG to cater for growing global demand and about CSL Behring’s steadfast commitment to addressing these challenges

PID – Africa and Middle East

Dr Nahla Hashim Hassan Erwa explains the complexities of diagnosis, treatment options and access to expert care that patients with primary immunodeficiency disorders in Africa and the Middle East face. She discusses the efforts that need to be made, and highlights the tireless work of patient groups and organisations in the region to raise the profile of these rare conditions with the goal of improving the lives of its citizens

IPOPI Article

Martine Pergent discusses the importance of increasing awareness and equal access to immunoglobulin (IG) and the work IPOPI is doing to address this, and highlights the growing tensions over IG shortages, not just across the Middle East and Africa but, alarmingly, at a global level

Be your brothers keeper Being diagnosed with a rare condition clearly has a huge impact on the person concerned but also on those living with and caring for them. Hellen Misati talks about life managing her daughter’s primary immunodeficiency disorder (PID), from issues of financial burden to a shortage of expertise and awareness. She shares her hopes and fears for her daughter’s future and the changes she would like

PID and plasma-derived therapies
Skip to content